Werbety Lucas Queiroz Feitosa

Werbety Lucas Queiroz Feitosa

Auto-generated profile, based on publicly available information

Werbety Lucas Queiroz Feitosa

Universidade Federal do Ceará, Faculdade de Medicina, Fortaleza CE, Brazil

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Dementia & Neuropsychologia
Verified
Journal Article
Open access
PDF file
JTJosé Wagner Leonel Tavares-Júnior
José Wagner Leonel Tavares-Júnior
GCGabriella Cunha Vieira Ciurleo
Gabriella Cunha Vieira Ciurleo
AFAlissa Moura Formiga
Alissa Moura Formiga
TVThais de Maria Frota Vasconcelos
Thais de Maria Frota Vasconcelos
MAMarcello Holanda de Andrade
Marcello Holanda de Andrade
PBPedro Braga-Neto
Pedro Braga-Neto
Infection with the SARS-CoV-2 virus can lead to neurological symptoms in the acute phase and in the Long COVID phase. These symptoms usually involve cognition, sleep, smell disorders, psychiatric manifestations, headache and others. This condition is more commonly described in young adults and women. This symptomatology can follow severe or mild cases of the disease. The importance of this issue resides in the high prevalence of neurological symptoms in the Long COVID phase, which entails significant morbidity in this population. In addition, such a condition is associated with high health care costs, with some estimates hovering around 3.7 trillion US dollars. In this review, we will sequentially describe the current knowledge about the most prevalent neurological symptoms in Long COVID, as well as their pathophysiology and possible biomarkers.

21 November 2023 in Brain Sciences
Verified
Journal Article
Open access
PDF file
JTJosé Wagner Leonel Tavares-Júnior
José Wagner Leonel Tavares-Júnior
DODanilo Nunes Oliveira
Danilo Nunes Oliveira
JSJean Breno Silveira da Silva
Jean Breno Silveira da Silva
WFWerbety Lucas Queiroz Feitosa
Werbety Lucas Queiroz Feitosa
ASArtur Victor Menezes Sousa
Artur Victor Menezes Sousa
PBPedro Braga-Neto
Pedro Braga-Neto
APOE ε4 polymorphism has been recently described as a possible association with cognitive deficits in COVID-19 patients. This research aimed to establish the correlation between COVID-19 and cognitive impairment, and the APOE gene polymorphism among outpatients. We performed a cross-sectional study with confirmed COVID-19 patients and neurological symptoms that persisted for more than three months from onset. APOE genotypes were determined. The final number of patients included in this study was 219, of which 186 blood samples were collected for APOE genotyping, evaluated 4.5 months after COVID-19. Among the participants, 143 patients (65.3%) reported memory impairment symptoms as their primary concern. However, this complaint was objectively verified through screening tests (Addenbrooke Cognitive Examination-Revised and Mini-Mental State Examination) in only 36 patients (16.4%). The group experiencing cognitive decline exhibited a higher prevalence of the APOE ε4 allele than the normal group (30.8% vs. 16.4%, respectively, p = 0.038). Furthermore, the APOE ε4 allele and anxiety symptoms remained significant after multivariate analysis. This study assessed an outpatient population where cognitive changes were the primary complaint, even in mild cases. Moreover, the ε4 allele, sleep disorders, and anxiety symptoms were more frequent in the cognitive decline group.

18 July 2024 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
PDF file
DODanilo Nunes Oliveira
Danilo Nunes Oliveira
JTJosé Wagner Leonel Tavares-Júnior
José Wagner Leonel Tavares-Júnior
WFWerbety Lucas Queiroz Feitosa
Werbety Lucas Queiroz Feitosa
LCLetícia Chaves Vieira Cunha
Letícia Chaves Vieira Cunha
CGCarmem Meyve Pereira Gomes
Carmem Meyve Pereira Gomes
PBPedro Braga-Neto
Pedro Braga-Neto
Background Olfactory dysfunction (OD) represents a frequent manifestation of the coronavirus disease 2019 (COVID-19). Apolipoprotein E (APOE) is a protein that interacts with the angiotensin-converting enzyme receptor, essential for viral entry into the cell. Previous publications have suggested a possible role of APOE in COVID-19 severity. As far as we know, no publications found significant associations between this disease's severity, OD, and APOE polymorphisms (E2, E3, and E4). Objective To analyze the epidemiology of OD and its relationship with APOE polymorphisms in a cohort of Long-COVID patients. Methods We conducted a prospective cohort study with patients followed in a post-COVID neurological outpatient clinic, with OD being defined as a subjective reduction of olfactory function after infection, and persistent OD being defined when the complaint lasted more than 3 months after the COVID-19 infection resolution. This cross-sectional study is part of a large research with previously reported data focusing on the cognitive performance of our sample. Results The final sample comprised 221 patients, among whom 186 collected blood samples for APOE genotyping. The persistent OD group was younger and had a lower hospitalization rate during the acute phase of the disease (p < 0.001). Furthermore, the APOE variant E4 allele frequency was lower in this group (p = 0.035). This study evaluated OD in an outpatient population with COVID-19. In the current literature on this disease, anosmia is associated with better clinical outcomes and the E4 allele is associated with worse outcomes. Conclusion Our study provides new information to these correlations, suggesting APOE E4 as a protective factor for OD.

16 June 2023 in Alzheimer's & Dementia
Verified
Journal Article
Open access
JTJosé Wagner Leonel Tavares-Júnior
José Wagner Leonel Tavares-Júnior
PBPedro Braga-Neto
Pedro Braga-Neto
MSMANOEL SOBREIRA
MANOEL SOBREIRA
RMRaquel Montenegro
Raquel Montenegro
CMCaroline DE Fátima Aquino Moreira
Caroline DE Fátima Aquino Moreira
DODanilo Nunes Oliveira
Danilo Nunes Oliveira
Background: COVID‐19 neurological manifestations were demonstrated during the pandemic, including cognitive impairment. Objectives: To determine the prevalence of cognitive and behavioral complaints (such as dementia, MCI or SCD) in a outpatient sample with recent SARS‐COV2 infection. Specific: Evaluate the association of cognitive impairment with the presence of the polymorphism found in the APOE gene and with respiratory diseaseMethod: Observational, longitudinal, prospective clinical study. Inclusion criteria: patients with confirmed Covid‐19. Patients are evaluated in an outpatient clinic. They are evaluated through a standardized attendance record, with somatic and cognitive neurological assessment. Cognitive assessment involves the application of cognitive (ACER, MMSE and CDR), functional (Pfeffer) and psychiatric (GDS or Beck) screening instruments, in addition to subsequent extensive neuropsychological assessment. In addition, APOE polymorphism is analysed.Results: To date, 200 patients were evaluated. The average age is 46.5 years, with 65.4% female, 79.16% with 8 or more years of schooling, in addition to 57.5% of the sample with cognitive complaints.Conclusions: The results so far in our study demonstrate that cognitive complaints are frequent in patients even in the chronic phase of the disease.